Inhibitory effect of Erigeron breviscapus extract and its flavonoid components on GABA shunt enzymes

Phytomedicine

Volumn 15, Issue 1-2, 2008, Pages 92-97

  Tao, Y H ^a,b   Jiang, D Y ^a   Xu, H B ^a   Yang, X L ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Erigeron breviscapus; Flavonoids; GABA transaminase; Inhibition; Structure activity relation; Succinic semialdehyde dehydrogenase

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; 4 AMINOBUTYRIC ACID; 4 HYDROXYBENZALDEHYDE; BAICALEIN; ERIGERON BREVISCAPUS EXTRACT; FLAVONOID; KAEMPFEROL; QUERCETIN; RUTOSIDE; SCUTELLAREIN; SUCCINATE SEMIALDEHYDE DEHYDROGENASE;

4 AMINOBUTYRIC ACID BRAIN LEVEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; ENZYME INHIBITION; GABAERGIC SYSTEM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC 50; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL ANALYSIS; STRUCTURE ACTIVITY RELATION;

4-AMINOBUTYRATE TRANSAMINASE; ANIMALS; APIGENIN; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ERIGERON; FLAVANONES; FLAVONOIDS; MALE; MOLECULAR STRUCTURE; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; SUCCINATE-SEMIALDEHYDE DEHYDROGENASE;

ERIGERON BREVISCAPUS;

EID: 37349057341     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phymed.2007.06.009     Document Type: Article

References (22)

1. Awad R., Arnason J.T., Trudeau V., Bergeron C., Budzinski J.W., Foster B.C., and Merali Z. Phytochemical and biological analysis of scullcap (Scutellaria lateriflora L.): a medicinal plant with anxiolytic properties. Phytomedicine 10 (2003) 640-649
2. Böhme I., and Lüddens H. The inhibitory neural circuitry as target of antiepileptic drugs. Curr. Med. Chem. 8 (2001) 1257-1274
3. Brodie J.D., Figueroa E., Laska E., and Dewey S.L. Safety and efficacy of γ-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse 55 (2005) 122-125
4. Chambliss K.L., and Gibson K.M. Succinic semialdehyde dehydrogenasefrom mammalian brain: subunit analysis using polyclonal antiserum. Int. J. Biochem. 24 (1992) 1493-1499
5. Choi S., Storici P., Schirmer T., and Silverman R.B. Design of a conformationally restricted analogue of the antiepilepsy drug vigabatrin that directs its mechanism of inactivation of γ-aminobutyric acid aminotransferase. J. Am. Chem. Soc. 124 (2002) 1620-1624
6. Chu Q., Wu T., Fu L., and Ye J. Simultaneous determination of active ingredients in Erigeron breviscapus (Vant.) Hand-Mazz. by capillary electrophoresis with electrochemical detection. J. Pharmaceut. Biomed. 37 (2005) 535-541
7. Churchich J.E., and Moses U. 4-Aminobutyrate aminotransferase. The presence of nonequivalent binding sites. J. Biol. Chem. 256 (1981) 1101-1104
8. C receptors. Eur. J. Pharmacol. 461 (2003) 79-87
9. Halonen T., Miettinen R., Toppinen A., Tuunanen J., Kotti T., and Riekkinen P.J. Vigabatrin protects against kainic acid-induced neuronal damage in the rat hippocampus. Neurosci. Lett. 195 (1995) 13-16
10. Huang J., Li N., Yu Y., Weng W., and Huang X. Determination of aglycone conjugated metabolites of scutellarin in rat plasma by HPLC. J. Pharm. Biomed. Anal. 40 (2006) 465-471
11. Johannessen C.U. Mechanisms of action of valproate: a commentatory. Neurochem. Int. 37 (2000) 103-110
12. Liu H., Yang X.L., Ding J.Y., Feng Y.D., and Xua H.B. Antibacterial and antifungal activity of Erigeron breviscapus. Fitoterapia 74 (2003) 387-389
13. Liu H., Yang X.L., Wang Y., Tang X.Q., Jiang D.Y., and Xu H.B. Protective effects of scutellarin on superoxide-induced oxidative stress in rat cortical synaptosomes. Acta Pharmacol. Sin. 24 (2003) 1113-1117
14. Liu H., Yang X., Tang R., Feng Y., and Xu H. Effects of Erigeron breviscapus ethanol extract on neuronal oxidative injury induced by superoxide radical. Fitoterapia 76 (2005) 666-670
15. Liu H., Yang X., Tang R., Liu J., and Xu H. Effect of scutellarin on nitric oxide production in early stages of neuron damage induced by hydrogen peroxide. Pharmacol. Res. 51 (2005) 205-210
16. Nguyen E., and Picklo Sr. M.J. Inhibition of succinic semialdehyde dehydrogenase activity by alkenal products of lipid peroxidation. Biochim. Biophys. Acta 1637 (2003) 107-112
17. Petroff O.A.C. GABA and glutamate in the human brain. Neuroscientist 8 (2002) 562-573
18. Qiu J., Pingsterhaus J.M., and Silverman R.B. Inhibition and substrate activity of conformationally rigid vigabatrin analogues with γ-aminobutyric acid aminotransferase. J. Med. Chem. 42 (1999) 4725-4728
19. Tao Y.H., Yuan Z., Tang X.Q., Xu H.B., and Yang X.L. Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. Bioorg. Med. Chem. Lett. 16 (2006) 592-595
20. Valdizán E.M., Garcia A.P., and Armijo J.A. Effects of increasing doses of vigabatrin on platelet γ-aminobutyric acid-transaminase and brain γ-aminobutyric acid in rats. Eur. J. Pharmacol. 369 (1999) 169-173
21. Yang X.F., He W., Lu W.H., and Zeng F.D. Effects of scutellarin on liver function after brain ischemia/reperfusion in rats. Acta Pharmacol. Sin. 24 (2003) 1118-1124
22. Zhong H., Deng Y., Wang X., and Yang B. Multivesicular liposome formulation for the sustained delivery of breviscapine. Int. J. Pharm. 301 (2005) 15-24